Value of triglyceride-glucose index combined with obesity index in predicting nonalcoholic fatty liver disease in individuals with obstructive sleep apnea

Rong JIANG; Yongxia LI

doi:10.3969/j.issn.1001-5256.2023.03.010

Volume 39 Issue 3

Mar. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(3): 546-551

PDF( 1893 KB)

Value of triglyceride-glucose index combined with obesity index in predicting nonalcoholic fatty liver disease in individuals with obstructive sleep apnea

DOI: 10.3969/j.issn.1001-5256.2023.03.010

Rong JIANG,
Yongxia LI^{,
,}

Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China

Research funding:

Graduate Student Innovation Fund of Kunming Medical University (2022S073)

More Information

Corresponding author: LI Yongxia, yongxiali999@163.com (ORCID: 0000-0002-8166-2211)
Received Date: 2022-07-31
Accepted Date: 2022-09-23
Published Date: 2023-03-20

Abstract

Abstract

Objective To investigate the value of triglyceride-glucose index (TyG), TyG combined with body mass index (BMI), and TyG combined with waist circumference (WC) in predicting nonalcoholic fatty liver disease (NAFLD) in patients with obstructive sleep apnea (OSA). Methods A retrospective analysis was performed for 190 patients who underwent sleep respiratory monitoring and were diagnosed with OSA in The Second Affiliated Hospital of Kunming Medical University from January 2020 to December 2021, and according to the results of ultrasonography, they were divided into OSA+NAFLD group with 107 patients and control group with 83 patients. The t-test or the Mann Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. The binary logistic regression analysis was used to explore the influencing factors for the development of NAFLD in patients with OSA. The receiver operating characteristic (ROC) curve was plotted for TyG, TyG combined with BMI, and TyG combined with WC in predicting NAFLD in the patients with OSA, and the area under the ROC curve (AUC) was calculated. The Z test was used for comparison of AUC. Results Compared with the control group, the OSA+NAFLD group had significantly higher BMI, neck circumference, WC, apnea-hypopnea index, oxygen desaturation index, alanine aminotransferase, gamma-glutamyltransferase, triglyceride, fasting plasma glucose, and TyG and significantly lower age, average SpO₂, LSaO₂, and high-density lipoprotein cholesterol (all P < 0.05). The binary logistic regression analysis showed that TyG (odds ratio [OR]=1.961, 95% confidence interval [CI]: 1.03-3.73, P=0.04), BMI (OR=1.203, 95%CI: 1.03-1.41, P=0.020), and WC (OR=1.074, 95%CI: 1.01-1.14, P=0.026) were independent risk factors for NAFLD in patients with OSA. TyG, TyG combined with BMI, and TyG combined with WC had an AUC of 0.696 (95%CI: 0.625-0.760), 0.787 (95%CI: 0.722-0.843), and 0.803 (95%CI: 0.739-0.857), respectively, in predicting NAFLD in OSA patients, with an optimal cut-off value of 8.72, 0.36, and 0.60, respectively. TyG combined with BMI had a significantly higher value than TyG in predicting NAFLD in OSA patients (Z=2.542, P=0.011), and TyG combined with WC also had a significantly higher predictive value than TyG (Z=2.976, P=0.002 9). Conclusion TyG, TyG combined with BMI, and TyG combined with WC have a good value in predicting NAFLD in OSA patients, among which TyG combined with WC has the best predictive value and is thus expected to become a predictor for the risk of NAFLD in OSA patients.
- Sleep Apnea, Obstructive,
- Non-alcoholic Fatty Liver Disease,
- Triglyceride-Glucose Index,
- Body Mass Index,
- Waist Circumference

FullText(HTML)

References(22)

References

[1]	BENJAFIELD AV, AYAS NT, EASTWOOD PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis[J]. Lancet Respir Med, 2019, 7(8): 687-698. DOI: 10.1016/S2213-2600(19)30198-5.
[2]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
[3]	UMBRO I, FABIANI V, FABIANI M, et al. Association between non-alcoholic fatty liver disease and obstructive sleep apnea[J]. World J Gastroenterol, 2020, 26(20): 2669-2681. DOI: 10.3748/wjg.v26.i20.2669.
[4]	KHAN SH, SOBIA F, NIAZI NK, et al. Metabolic clustering of risk factors: evaluation of Triglyceride-glucose index (TyG index) for evaluation of insulin resistance[J]. Diabetol Metab Syndr, 2018, 10: 74. DOI: 10.1186/s13098-018-0376-8.
[5]	SONG K, LEE HW, CHOI HS, et al. Comparison of the Modified TyG indices and other parameters to predict non-alcoholic fatty liver disease in youth[J]. Biology (Basel), 2022, 11(5): 685. DOI: 10.3390/biology11050685.
[6]	Sleep Medicine Committee of Chinese Medical Doctor Association. Guidelines for multidisciplinary diagnosis and treatment of adult obstructive sleep apnea[J]. Natl Med J China, 2018, 98(24): 1902-1914. DOI: 10.3760/cma.j.issn.0376-2491.2018.24.003. 中国医师协会睡眠医学专业委员会. 成人阻塞性睡眠呼吸暂停多学科诊疗指南[J]. 中华医学杂志, 2018, 98(24): 1902-1914. DOI: 10.3760/cma.j.issn.0376-2491.2018.24.003.
[7]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expen Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[8]	SIMENTAL-MENDÍA LE, RODRÍGUEZ-MORÁN M, GUERRERO-ROMERO F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects[J]. Metab Syndr Relat Disord, 2008, 6(4): 299-304. DOI: 10.1089/met.2008.0034.
[9]	DELONG ER, DELONG DM, CLARKE-PEARSON DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach[J]. Biometrics, 1988, 44(3): 837-845.
[10]	MESARWI OA, LOOMBA R, MALHOTRA A. Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease[J]. Am J Respir Crit Care Med, 2019, 199(7): 830-841. DOI: 10.1164/rccm.201806-1109TR.
[11]	JIN S, JIANG S, HU A. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Sleep Breath, 2018, 22(3): 841-851. DOI: 10.1007/s11325-018-1625-7.
[12]	CHEN LD, ZHANG LJ, LIN XJ, et al. Association between continuous positive airway pressure and serum aminotransferases in patients with obstructive sleep apnea[J]. Eur Arch Otorhinolaryngol, 2018, 275(2): 587-594. DOI: 10.1007/s00405-017-4840-0.
[13]	CAKMAK E, DUKSAL F, ALTINKAYA E, et al. Association between the severity of nocturnal hypoxia in obstructive sleep apnea and non-alcoholic fatty liver damage[J]. Hepat Mon, 2015, 15(11): e32655. DOI: 10.5812/hepatmon.32655.
[14]	LIU YR, WEN XH, GAO M, et al. Correlation between atherogenic index of plasma and nonalcoholic fatty liver disease in non-obese populations[J]. Clin Misdiagn Misther, 2021, 34(10): 100-104. DOI: 10.3969/j.issn.1002-3429.2021.10.021. 刘艳如, 温晓华, 高冕, 等. 非肥胖人群血浆致动脉硬化指数与非酒精性脂肪性肝病的相关性[J]. 临床误诊误治, 2021, 34(10): 100-104. DOI: 10.3969/j.issn.1002-3429.2021.10.021.
[15]	BETTINI S, SERRA R, FABRIS R, et al. Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study[J]. Eat Weight Disord, 2021, 27(1): 335-343. DOI: 10.1007/s40519-021-01182-9.
[16]	FU YM, WANG CY, LI ZB, et al. Diagnostic efficiency of controlled attenuation parameter on hepatic steatosis of patients with nonalcoholic fatty liver disease[J]. Med J Chin PLA, 2022, 47(6): 593-598. DOI: 10.11855/j.issn.0577-7402.2022.06.0593. 付懿铭, 王春艳, 李忠斌, 等. 受控衰减参数对非酒精性脂肪性肝病患者肝脂肪变性分级的诊断价值[J]. 解放军医学杂志, 2022, 47(6): 593-598. DOI: 10.11855/j.issn.0577-7402.2022.06.0593.
[17]	STAREKOVA J, HERNANDO D, PICKHARDT PJ, et al. Quantification of liver fat content with CT and MRI: State of the art[J]. Radiology, 2021, 301(2): 250-262. DOI: 10.1148/radiol.2021204288.
[18]	ER LK, WU S, CHOU HH, et al. Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals[J]. PLoS One, 2016, 11(3): e0149731. DOI: 10.1371/journal.pone.0149731.
[19]	LEE SB, KIM MK, KANG S, et al. Triglyceride glucose index is superior to the homeostasis model assessment of insulin resistance for predicting nonalcoholic fatty liver disease in Korean adults[J]. Endocrinol Metab (Seoul), 2019, 34(2): 179-186. DOI: 10.3803/EnM.2019.34.2.179.
[20]	KIM HS, CHO YK, KIM EH, et al. Triglyceride glucose-waist circumference is superior to the homeostasis model assessment of insulin resistance in identifying nonalcoholic fatty liver disease in healthy subjects[J]. J Clin Med, 2021, 11(1): 41. DOI: 10.3390/jcm11010041.
[21]	KHAMSEH ME, MALEK M, ABBASI R, et al. Triglyceride glucose index and related parameters (triglyceride glucose-body mass index and triglyceride glucose-waist circumference) identify nonalcoholic fatty liver and liver fibrosis in individuals with overweight/obesity[J]. Metab Syndr Relat Disord, 2021, 19(3): 167-173. DOI: 10.1089/met.2020.0109.
[22]	FERRAIOLI G, SOARES MONTEIRO LB. Ultrasound-based techniques for the diagnosis of liver steatosis[J]. World J Gastroenterol, 2019, 25(40): 6053-6062. DOI: 10.3748/wjg.v25.i40.6053.

Relative Articles

[1]	Long HAI, Lina MA, Xia LUO, Xiangchun DING. Effect of miRNA-933 on the apoptosis and proliferation of LX-2 cells and its molecular mechanism[J]. Journal of Clinical Hepatology, 2024, 40(7): 1382-1389. doi: 10.12449/JCH240716
[2]	Yao ZHANG, Kai ZHANG, Pengdong KANG, Chao MA. Research advances in microRNA-200c in pancreatic cancer[J]. Journal of Clinical Hepatology, 2022, 38(4): 961-964. doi: 10.3969/j.issn.1001-5256.2022.04.045
[3]	Sheng CHEN, Guoxiang CHEN, Zhongming HE, Shujie CHENG, Jisen ZHAO. Role of miRNA in the development and progression of cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2021, 37(9): 2241-2245. doi: 10.3969/j.issn.1001-5256.2021.09.048
[4]	Huijun XIE, Nasot Rashed, Yong NING, Chuan GAO. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 448-451. doi: 10.3969/j.issn.1001-5256.2021.02.042
[5]	Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
[6]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[7]	Wu Jie, Li JingTao, Wei HaiLiang, Yan ShuGuang, Fan Yu, Guo YingJun, Chang ZhanJie. Advances in the role of microRNA in the intervention of malignant transformation of precancerous lesions of the liver by regulating the activation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2020, 36(7): 1650-1654. doi: 10.3969/j.issn.1001-5256.2020.07.045
[8]	Guo Xuan, Tan Wei, Wang ChangJun. Mechanism of action of circular RNAs in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2340-2343. doi: 10.3969/j.issn.1001-5256.2020.10.039
[9]	Cheng YaFei, Wang Bin, Wang ShiMing. Role of microRNAs in gallbladder carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1900-1904. doi: 10.3969/j.issn.1001-5256.2020.08.049
[10]	Wang ZeXin, Guan LiJun, Li JianMing, Wang ZhiChao, Xue MengRuo, Qin XiaoJun. Effect of targeted regulation of the Wnt2 gene by microRNA( microRNA-21) on the proliferation and migration of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 803-807. doi: 10.3969/j.issn.1001-5256.2020.04.019
[11]	Wu JunYi, Lai ZhiDe, Tian YiFeng, Wang YaoDong. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1768-1772. doi: 10.3969/j.issn.1001-5256.2020.08.018
[12]	Huang XiangJun, Zhang WenXing. Expression features and clinical significance of the microRNA-888 gene family in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 119-122. doi: 10.3969/j.issn.1001-5256.2019.01.022
[13]	Niu YaQian, Chang YuLing, Liu Fang, Zhao Chuan, Chen Che. Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(9): 2082-2084. doi: 10.3969/j.issn.1001-5256.2019.09.044
[14]	Zhang ZhuQing, Lu ShuMing, Wang HuaLi, Xu MengYao, Li ChunYan, Xin Yue, Zhao JunJun. Expression of microRNA-222 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of Clinical Hepatology, 2017, 33(8): 1502-1505. doi: 10.3969/j.issn.1001-5256.2017.08.018
[15]	Wang DongXu, Huo TingTing, Tian YaoWen, Zhao Lei. Current status of research on microRNA associated with colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2387-2390. doi: 10.3969/j.issn.1001-5256.2016.12.034
[16]	Qiu Hua, Sun XueHua, Zhou ZhenHua, Li Man, Zhang Xin, Gao YueQiu. Influence of interaction between endogenous miRNAs and hepatitis B virus in hepatocytes on hepatitis B virus transcription and related mechanisms[J]. Journal of Clinical Hepatology, 2016, 32(11): 2186-2190. doi: 10.3969/j.issn.1001-5256.2016.11.042
[17]	Xiao ZuoHan, Meng Gang, Wang LiZhi, Sun WenJin. Diagnostic value of combined determination of DNA ploidy level and miRNA-21 expression in ascites cells for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(1): 93-98. doi: 10.3969/j.issn.1001-5256.2015.01.020
[18]	Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs[J]. Journal of Clinical Hepatology, 2015, 31(6): 977-981. doi: 10.3969/j.issn.1001-5256.2015.06.037
[19]	Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008
[20]	Guo JinSheng. Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy [J]. Journal of Clinical Hepatology, 2013, 29(5): 324-326.

Supplements(0)

Cited By

Cited by

Periodical cited type(1)

孙巍，丁晓燕，陈京龙，李文东，郭晓笛，申燕军，滕颖，刘晓民，魏建莹. MicroRNA-520a通过失活AKT抑制HepG2.2.15细胞中HBV DNA复制. 中国肝脏病杂志(电子版). 2018(04): 73-78 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (648) PDF downloads(94)

Value of triglyceride-glucose index combined with obesity index in predicting nonalcoholic fatty liver disease in individuals with obstructive sleep apnea

DOI: 10.3969/j.issn.1001-5256.2023.03.010